Nanotechnology for Tau Pathology in Alzheimer's Disease

Overview

Journal Mater Today Bio

Specialty Biomedical Engineering

Date 2024 Jul 29

PMID 39070098

Authors

Rongrong Ma

Qianwen Mu

Yue Xi

Gang Liu

Chao Liu

Affiliations

Soon will be listed here.

Abstract

Tau protein aggregation is a defining characteristic of Alzheimer's disease (AD), leading to the formation of neurofibrillary tangles that disrupt neural communication and ultimately result in cognitive decline. Nanotechnology presents novel strategies for both diagnosing and treating Alzheimer's disease. Nanotechnology. It has become a revolutionary tool in the fight against Alzheimer's disease, particularly in addressing the pathological accumulation of tau protein. This review explores the relationship between tau-related neurophysiology and the utilization of nanotechnology for AD treatment, focusing on the application of nanomaterials to regulate tau phosphorylation, hinder tau aggregation and propagation, stabilize microtubules, eliminate pathological tau and emphasize the potential of nanotechnology in developing personalized therapies and monitoring treatment responses in AD patients. This review combines tau-related neurophysiology with nanotechnology to provide new insights for further understanding and treating Alzheimer's disease.

Citing Articles

Decoding Neurodegeneration: A Review of Molecular Mechanisms and Therapeutic Advances in Alzheimer's, Parkinson's, and ALS.

Toader C, Tataru C, Munteanu O, Serban M, Covache-Busuioc R, Ciurea A Int J Mol Sci. 2024; 25(23.

PMID: 39684324 PMC: 11641752. DOI: 10.3390/ijms252312613.

References

Cheng W, Su Y, Hsu H, Lin Y, Chu L, Huang W . Rabies Virus Glycoprotein-Mediated Transportation and T Cell Infiltration to Brain Tumor by Magnetoelectric Gold Yarnballs. ACS Nano. 2022; 16(3):4014-4027. DOI: 10.1021/acsnano.1c09601. View

Drummond E, Pires G, Macmurray C, Askenazi M, Nayak S, Bourdon M . Phosphorylated tau interactome in the human Alzheimer's disease brain. Brain. 2020; 143(9):2803-2817. PMC: 7526722. DOI: 10.1093/brain/awaa223. View

Zhang L, Xie X, Liu D, Xu Z, Liu R . Efficient co-delivery of neo-epitopes using dispersion-stable layered double hydroxide nanoparticles for enhanced melanoma immunotherapy. Biomaterials. 2018; 174:54-66. DOI: 10.1016/j.biomaterials.2018.05.015. View

Hanger D, Anderton B, Noble W . Tau phosphorylation: the therapeutic challenge for neurodegenerative disease. Trends Mol Med. 2009; 15(3):112-9. DOI: 10.1016/j.molmed.2009.01.003. View

Goedert M, Spillantini M, Jakes R, Rutherford D, Crowther R . Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease. Neuron. 1989; 3(4):519-26. DOI: 10.1016/0896-6273(89)90210-9. View

Lindwall G, Cole R . Phosphorylation affects the ability of tau protein to promote microtubule assembly. J Biol Chem. 1984; 259(8):5301-5. View

Wang S, Su R, Nie S, Sun M, Zhang J, Wu D . Application of nanotechnology in improving bioavailability and bioactivity of diet-derived phytochemicals. J Nutr Biochem. 2014; 25(4):363-76. PMC: 3959237. DOI: 10.1016/j.jnutbio.2013.10.002. View

Guo T, Noble W, Hanger D . Roles of tau protein in health and disease. Acta Neuropathol. 2017; 133(5):665-704. PMC: 5390006. DOI: 10.1007/s00401-017-1707-9. View

Congdon E, Gu J, Sait H, Sigurdsson E . Antibody uptake into neurons occurs primarily via clathrin-dependent Fcγ receptor endocytosis and is a prerequisite for acute tau protein clearance. J Biol Chem. 2013; 288(49):35452-65. PMC: 3853292. DOI: 10.1074/jbc.M113.491001. View

10.

Harada A, Oguchi K, Okabe S, KUNO J, Terada S, Ohshima T . Altered microtubule organization in small-calibre axons of mice lacking tau protein. Nature. 1994; 369(6480):488-91. DOI: 10.1038/369488a0. View

11.

Drechsel D, Hyman A, Cobb M, Kirschner M . Modulation of the dynamic instability of tubulin assembly by the microtubule-associated protein tau. Mol Biol Cell. 1992; 3(10):1141-54. PMC: 275678. DOI: 10.1091/mbc.3.10.1141. View

12.

Ling D, Lee N, Hyeon T . Chemical synthesis and assembly of uniformly sized iron oxide nanoparticles for medical applications. Acc Chem Res. 2015; 48(5):1276-85. DOI: 10.1021/acs.accounts.5b00038. View

13.

Goate A, Chartier-Harlin M, Mullan M, Brown J, Crawford F, Fidani L . Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature. 1991; 349(6311):704-6. DOI: 10.1038/349704a0. View

14.

Wood J, Mirra S, Pollock N, Binder L . Neurofibrillary tangles of Alzheimer disease share antigenic determinants with the axonal microtubule-associated protein tau (tau). Proc Natl Acad Sci U S A. 1986; 83(11):4040-3. PMC: 323661. DOI: 10.1073/pnas.83.11.4040. View

15.

Chen K, Yu R, Zhong C, Wang Z, Xie B, Ma H . Electrochemical Monitoring of Real-Time Vesicle Dynamics Induced by Tau in a Confined Nanopipette. Angew Chem Int Ed Engl. 2024; 63(39):e202406677. DOI: 10.1002/anie.202406677. View

16.

Shaw-Smith C, Pittman A, Willatt L, Martin H, Rickman L, Gribble S . Microdeletion encompassing MAPT at chromosome 17q21.3 is associated with developmental delay and learning disability. Nat Genet. 2006; 38(9):1032-7. DOI: 10.1038/ng1858. View

17.

Hu Y, Gao J . Potential neurotoxicity of nanoparticles. Int J Pharm. 2010; 394(1-2):115-21. DOI: 10.1016/j.ijpharm.2010.04.026. View

18.

Kundel F, Hong L, Falcon B, McEwan W, Michaels T, Meisl G . Measurement of Tau Filament Fragmentation Provides Insights into Prion-like Spreading. ACS Chem Neurosci. 2018; 9(6):1276-1282. PMC: 6014609. DOI: 10.1021/acschemneuro.8b00094. View

19.

Medina M, Avila J . Further understanding of tau phosphorylation: implications for therapy. Expert Rev Neurother. 2015; 15(1):115-22. DOI: 10.1586/14737175.2015.1000864. View

20.

Chen D, Joachimiak L . Cross-Linking Mass Spectrometry Analysis of Metastable Compact Structures in Intrinsically Disordered Proteins. Methods Mol Biol. 2022; 2551:189-201. DOI: 10.1007/978-1-0716-2597-2_13. View